OrthoPediatrics Corps Reveals Third Quarter Insights and Updates
OrthoPediatrics Third Quarter Update
OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic field, has shared its preliminary unaudited financial results for the third quarter of 2025, outlining the company’s successes and adjustments for the upcoming year. The company, dedicated to enhancing the lives of children with orthopedic conditions, showcased a strong performance in helping young patients while forecasting strategic changes in its guidance.
Highlights from the Third Quarter
In the third quarter of 2025, OrthoPediatrics made a significant impact, assisting over 37,100 children and bringing the total served since its inception to approximately 1.3 million. The preliminary revenue figures reflect a robust operational performance: the company reported an estimated net revenue of about $61.2 million, marking a growth of 12% from the same period in 2024. Domestic revenue accounted for approximately $48.7 million, showcasing an impressive 14% year-over-year increase, while international revenue was expected to reach around $12.5 million, a 6% growth in the same timeframe.
Detailed Revenue Growth Analysis
When excluding 7D capital sales, the preliminary net revenue for the third quarter amounted to $60.7 million, indicating a notable 17% increase compared to $51.8 million from the third quarter of the previous year. The domestic market, excluding these capital sales, contributed approximately $48.2 million and demonstrated a 19% growth over the prior year’s numbers. OrthoPediatrics' leadership acknowledged the variability related to the timing of capital sales and emphasized their transparent approach in updating their financial expectations for the rest of 2025.
Updated Financial Guidance for 2025
Looking ahead, OrthoPediatrics has revised its 2025 revenue guidance to a range of $233.5 million to $234.5 million, a reduction from the earlier prediction of $237.0 million to $242.0 million. They project growth of 14% to 15% compared to revenue from 2024. The company is also maintaining an anticipated annual set deployment at $15.0 million, as well as adjusted EBITDA guidance between $15.0 million to $17.0 million for the same year.
Operational Challenges and Commitment
David Bailey, President & CEO of OrthoPediatrics, addressed the challenges faced in the latter part of September, particularly the delays in 7D capital sales and fluctuations in the Latin and South American markets. These factors were acknowledged as the primary reasons for the revenue shortfall against the company’s expectations. Despite these hurdles, Bailey reaffirmed the commitment of OrthoPediatrics to driving profitable growth, which aims to reach cash flow break-even by 2026. He emphasized that their extensive product portfolio, comprising OPSB braces and services, positions them uniquely in the pediatric orthopedic market.
Future Engagements and Financial Transparency
The preliminary net revenue estimates disclosed by OrthoPediatrics are subject to adjustments pending the completion of reviews by their independent auditors. To ensure maximum transparency, the company plans to hold a conference call to discuss these results, providing interested investors the opportunity to gain additional insights into their financial performance.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is exclusively committed to the pediatric orthopedic sector, having developed an extensive range of products aimed at improving the quality of life for children with orthopedic challenges. With over 80 products available, OrthoPediatrics specializes in areas such as trauma, deformity correction, scoliosis, and sports medicine. Their global sales capabilities extend to over 70 countries, ensuring that their impact is felt worldwide.
Frequently Asked Questions
What were OrthoPediatrics' revenue results for Q3 2025?
The preliminary net revenue for Q3 2025 was approximately $61.2 million, marking a 12% increase compared to the same quarter in 2024.
What is the updated revenue guidance for OrthoPediatrics in 2025?
The revised revenue guidance for 2025 is set between $233.5 million and $234.5 million, which is lower than previous forecasts.
How many children has OrthoPediatrics served?
OrthoPediatrics has helped over 1.3 million children since its inception.
What challenges did the company face recently?
The company faced challenges such as delays in 7D capital sales and fluctuations in the Latin and South American markets, affecting revenue expectations.
What is the significance of the OPSB braces?
The OPSB braces are an essential part of OrthoPediatrics' comprehensive product offering, designed to support children's orthopedic needs.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.